{"url":"https://lda.senate.gov/api/v1/filings/237c7bd5-43ff-4c8e-bcdb-017daf4fd60d/","filing_uuid":"237c7bd5-43ff-4c8e-bcdb-017daf4fd60d","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2023,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/237c7bd5-43ff-4c8e-bcdb-017daf4fd60d/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Julie Chan","dt_posted":"2023-10-19T02:29:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1601 Trapelo Rd., Ste 178","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Waltham","registrant_state":"MA","registrant_zip":"02451","registrant":{"id":401106767,"url":"https://lda.senate.gov/api/v1/registrants/401106767/","house_registrant_id":45693,"name":"INVIVYD, INC.","description":null,"address_1":"209 Church Street","address_2":null,"address_3":null,"address_4":null,"city":"New Haven","state":"CT","state_display":"Connecticut","zip":"06510","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BEN KENNEY","contact_telephone":"+1 202-491-1420","dt_updated":"2026-06-24T15:04:25.330219-04:00"},"client":{"id":52240,"url":"https://lda.senate.gov/api/v1/clients/52240/","client_id":52240,"name":"INVIVYD, INC.","general_description":"education and awareness related to COVID-19 therapeutics","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-05-05"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138459,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":null,"last_name":"CHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":21,"name":"Office of Science & Technology Policy (OSTP)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"education and awareness of COVID-19 therapeutics","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138459,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":null,"last_name":"CHAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":21,"name":"Office of Science & Technology Policy (OSTP)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}